Financial Performance - Q2 2025 revenue reached $219 million, a 14% year-over-year increase[26] - Annual Run-rate Revenue (ARR) grew to $875 million, also a 14% year-over-year increase[26] - Net Dollar Retention Rate (NDR) improved to 99%, a 200 bps increase[26] - Average Revenue per User (ARPU) increased by 12% to $111.70[26] - The company is raising full year revenue guidance to $888 to $892 million[21] - Adjusted Free Cash Flow Margin for Q2 2025 was 26%, with a trailing twelve months margin of 14%[35] Customer Growth - Digital Native Enterprise (DNE) customers expanded to 174,000[21] - Scalers+ (>$100K Annual run rate) are growing at 35% and represent 24% of revenue[21] - Higher Spend Customers (Builders, Scalers, and Scalers+) represent 89% of total company revenue[41] Product and Innovation - Launched 60 new features across Cloud and AI stack[22] - General Availability (GA) of DigitalOcean Gradient AI Platform[22] Market Focus - The company focuses on the $140 billion Digital Native Enterprises market[11]

Company Overview - SOPHiA GENETICS' Ai platform SOPHiA DDM™ is used by over 800 healthcare institutions globally to analyze complex health data for cancer and rare disorders[7] - The platform analyzes over 350,000 patients annually and has analyzed over 2 million profiles since its inception[8, 21] - The company has invested over $450 million since its inception in its Ai platform[21, 57] Market Trends - The incidence of cancer and rare disorders is increasing worldwide, driving demand for targeted therapies[13] - Healthcare data is rapidly expanding, with 30% of all data generated globally being healthcare-related[16] - The Total Addressable Market (TAM) for Liquid Biopsy is estimated to be over $5 billion[56] Financial Performance - SOPHiA GENETICS' revenue for 2024 was $65.2 million[60] - The company projects revenue between $72 million and $76 million for 2025, representing a year-over-year growth of approximately 10% to 17%[60, 63] - Adjusted EBITDA loss is projected to be between $35 million and $39 million in 2025, compared to $40.2 million in 2024[63] - The company's adjusted gross margin was 72.8% in 2024 and is expected to expand slightly in 2025[63]

Transaction Overview - Blade Passenger division 将以高达 1.25 亿美元的价格出售给 Joby Aviation[9]，这笔交易的价格可能会以现金或 Joby 股票支付[10] - Blade 的医疗部门将保留公开上市资格，并更名为 Strata Critical Medical ("Strata")，成为一家纯粹的合同医疗业务公司[9] - 预计资产剥离在调整后的 EBITDA 和自由现金流方面将保持中性，并得到约 700 万美元的年度企业成本效率的支持[9] Financial Performance (Q2 2025) - Medical 部门收入同比增长 18%[18] - Passenger 部门收入同比下降 13%[13] - Medical 部门调整后的 EBITDA 利润率为 13.4%，同比下降 1 个百分点[18] - Passenger 部门调整后的 EBITDA 同比增长 160 万美元[18] - 短途收入（不包括加拿大）同比下降 6%[18] Medical Segment Growth Drivers - 2018 年至 2024 年，心脏、肝脏和肺移植距离增加了 64%[38] - Blade 在器官移植航空物流领域的市场份额估计约为 30%[40] - 地面运输的总潜在市场为 2 亿美元[46] - 器官配置服务的总潜在市场约为 2.5 亿美元[53] Trinity Air Medical Acquisition Impact - 截至 2024 年 9 月 30 日的 12 个月内，Blade/Trinity Medical 部门的总收入约为 1.42 亿美元，分部调整后的 EBITDA 为 1630 万美元[62]

Financial Performance - Total revenue reached $82.4 million, a 12% increase[7,40] - U S net product sales increased by 42% to $40.3 million[7,40] - Collaboration revenue was $42.1 million, a 7% decrease, but adjusting for a one-time settlement agreement milestone with DSE received in Q2 2024, it represents a 105% increase[40] - The company achieved its first quarter of operating income from ongoing business and anticipates sustainable profitability beginning in Q1 2026[4,40] - Cash and cash equivalents stand at $86.1 million[43] Marketing and Sales - Over 28,000 healthcare providers are now writing prescriptions for the company's products[9,20] - Retail prescription equivalents increased by 10% compared to Q1 2025[7,20,48] - The consumer statin intolerance website received over 650,000 visits in Q2, and the HCP statin intolerance site had over 600,000 click-throughs[15] - A balanced direct and digital marketing approach resulted in 23% of prescriptions written by physicians with only digital touchpoints and 38% of new writer prescriptions driven by digital-only touchpoints[17,20] Pipeline and Strategic Initiatives - The company is advancing IND-enabling studies for a new program in primary sclerosing cholangitis (PSC), representing an approximately $1 billion annual market opportunity, with potential first-in-human studies in 2H 2026[25,36] - Settlements were reached with three ANDA filers to protect NEXLETOL's IP until 2040[25]

Rhythm Pharmaceuticals Second Quarter 2025 Financial Results and Business Update August 5, 2025 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. On Today's Call ® ® 2 • David Connolly, Executive Director of Investor Relations and Corporate Communications • David Meeker, MD, Chair, President and Chief Executive Officer • Jennifer Lee, Executive Vice President, Head of North America • Yann Mazabraud, Executive Vice President, Head of International • Hunter Smith, Chief Financial Officer Forward-looking ...

Strategic Transformation - SVC is transforming into a majority net lease REIT by selling a significant portion of its hotel portfolio[10, 18] - Anticipated gross proceeds from hotel sales in 2025 are $966 million[21] - Net lease assets will represent 71% of pro forma Adjusted EBITDAre for LTM 2Q25 after the hotel sales[21] - 114 hotels (14,925 keys) are earmarked for sale in 2H25, with $900 million under binding agreement[21] Financial Highlights - SVC's LTM Adjusted EBITDAre is $565.238 million[147] - Pro Forma Net Debt / LTM Adjusted EBITDAre is expected to be 93x after hotel dispositions[40] - SVC has $60 billion of unencumbered assets pro forma for anticipated hotel dispositions[45] Net Lease Portfolio - The net lease portfolio has 742 properties with $3865 million in annualized minimum rent[13] - TravelCenters of America (TA) accounts for 68% of annualized minimum net lease rents as of 2Q25[21] - Approximately 97% of net leases have embedded growth through contractual rent escalators[21] Hotel Portfolio - The pro forma hotel portfolio will consist of 84 hotels with 19,942 keys[23, 29] - The pro forma hotel portfolio is expected to generate $144 million in EBITDA[29] - The ADR for the pro forma hotel portfolio is expected to be $17180 and RevPAR is expected to be $10840[29]

Financial Performance - System sales grew by 4% YoY in Q2, excluding F/X impact[5] - Same-store sales increased by 1% YoY in Q2[5] - Operating Profit reached $304 million in Q2, a 14% increase YoY[5] - Diluted EPS grew to $0.58, a 5% increase YoY, or 15% excluding mark-to-market impact & F/X[5] - Digital sales exceeded $5 billion in 1H 2025[15] Store Expansion and Franchising - The company added 336 net new stores in Q2 and 583 in 1H[7] - Net new unit contribution to system sales was 4% in Q2[7] - KFC has 12,238 total stores, with 14% franchised[10] - Pizza Hut has 3,864 total stores, with 6% franchised[10] Brand Performance - KFC system sales grew by 5% YoY, with a 1% increase in same-store sales in Q2[20] - KFC's operating profit margin was 14%, a 90 bps increase YoY[20] - Pizza Hut system sales grew by 3% YoY, with a 2% increase in same-store sales in Q2[27] - Pizza Hut's operating profit grew by 16% YoY, with an operating profit margin of 83%, a 90 bps increase YoY[27] Capital Returns - The company targets $3 billion in capital returns for 2025-26 and $45 billion for 2024-26[37] - Net cash by the end of June 2025 was $28 billion[37]

Financial Performance & Growth - Westgold achieved a record Q4 FY25 and FY25, closing with $364 million in cash, bullion, and liquid investments[33, 34] - In Q4 FY25, Westgold produced 88,022 ounces of gold at an AISC (All-In Sustaining Cost) of $2,688/oz and sold 71,500 ounces at an average price of A$5,174/oz, generating revenue of A$370 million[36] - Westgold reported a record quarterly treasury build of $132 million in Q4 FY25[27, 36] Operational Highlights & Future Plans - Westgold is transitioning to predominantly longitudinal open stoping at the South-Junction mine, expecting paste fill to commence in late Q1 FY26, enabling 100% orebody extraction[41] - Great Fingall virgin stopes are expected to bring higher grade ore, with first ore to the Bluebird mill in Q2 FY26, displacing low-grade stockpiles[44] - Westgold plans to expand Beta Hunt to >2Mtpa with infrastructure projects progressing, including clean water supply and primary vent upgrades[50] - The company aims to expand Bluebird-South Junction to 1.2Mtpa and grow the Fletcher Zone[69] Resource & Reserve Updates - The Fletcher Zone Maiden Mineral Resource was reported as 31 million tonnes @ 2.3g/t for 2.3 million ounces of gold at the end of Q4 FY25[56, 85] - At the end of Q1 FY25, the Bluebird-South Junction Mineral Resource was reported as 14.969 million tonnes @ 2.9g/t for 1.37 million ounces of gold[85] - At the end of Q1 FY25, the Starlight Open Pit & Underground Mineral Resource was reported as 12.9 million tonnes @ 2.7g/t for 1.13 million ounces of gold[85]

Project Overview - Antipa Minerals holds a 100% ownership of the Paterson Province landholding, featuring the Minyari Dome gold-copper development project[1] - The project has a pre-tax NPV7% of A$834 million at a gold price of A$3,000 per ounce[16, 21] - The project has a gold equivalent resource of 2.9 million ounces[21] - The project has a contained gold only resource of 2.4 million ounces[21] Financials and Operations - The initial gold output is projected at 1.3 million ounces, averaging 130,000 ounces per year for the first 10 years[21] - The initial capital cost is estimated at A$306 million, including A$90 million for pre-production mining[21] - The project anticipates a 3 Mtpa throughput for a 10+ year initial processing life[21] - The project has an IRR of 52% pre-tax at a gold price of A$3,000 per ounce[21] Exploration and Resources - The company has A$71 million cash position[16] - The company has a land package of over 4,100km2[16] - The company has a mineral resource of 2.5 Moz of gold, 84,000 t of copper, and 666 koz of silver[16]

Production and Growth - The company targets an increased production of 175-195 thousand ounces of gold per annum in FY27[26] - FY26 production guidance is set at 130-150 thousand ounces of gold, with an All-In Sustaining Cost (AISC) between A$2,600-2,900 per ounce[41] - FY25 saw a total gold production of 126 thousand ounces, with 130 thousand ounces sold at an AISC of A$2,422 per ounce[41] - The company has an exploration target of 1.5-2.5 million ounces of gold down plunge from known mineralization[26] Resources and Reserves - The company's global Mineral Resource stands at 3.1 million ounces of gold, comprising 6.3 million tonnes at 9.7 g/t gold for 2.0 million ounces Indicated and 4.4 million tonnes at 7.9 g/t gold for 1.1 million ounces Inferred[27] - The Probable Underground Ore Reserve is 8.48 million tonnes at 4.7 g/t gold for 1.28 million ounces, with a total Ore Reserve of 8.57 million tonnes at 4.7 g/t gold for 1.29 million ounces[115] Financial Position - As of June 30, 2025, the company had A$152 million in total liquidity, with a net cash position of A$52 million after accounting for A$100 million in bank debt[37] - The company has forward gold sales commitments totaling 152,000 ounces at an average price of A$2,843 per ounce[38] Sustainability - The Bellevue Gold Project has achieved net zero (Scope 1 and Scope 2) greenhouse gas emissions for H1 CY25[9, 112] - The company's power station has a 90 MW hybrid capacity, including 24 MW wind, 27 MW solar, 24 MW thermal, and a 15 MW/ 29 MWh Battery Energy Storage Solution (BESS)[101]